Get started
Author

Valentín Ortiz‐Maldonado

Observed names: Ortiz-Maldonado, Valentín, V Ortiz-Maldonado, V. Ortiz-Maldonado, V. Ortiz‐Maldonado, Valentin Ortiz, Valentin Ortiz-Maldonado, Valentin Ortiz‐Maldonado, Valentín Ortiz Maldonado, Valentín Ortiz-Maldonado, Valentín Ortíz, Valentín Ortíz-Maldonado
Observed institutions: Instituto de Salud Carlos III, John Radcliffe Hospital, University of Oxford, Fred Hutch Cancer Center, MRC Weatherall Institute of Molecular Medicine, Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Cáncer, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona
ORCID: 0000-0003-4699-6862
Observed ORCID: 0000-0003-4699-6862
OpenAlex ID: A5046330090
Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
2023 · Benno Lickefett, Lulu Chu, et al. · Frontiers in Immunology · 178
PDF
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies
2020 · Valentín Ortíz-Maldonado, Susana Rives, et al. · Molecular Therapy · 163
PDF
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
2023 · Nicolas Gazeau, Emily C. Liang, et al. · Transplantation and Cellular Therapy · 157
Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial
2020 · Maria Castella, Miguel Caballero-Baños, et al. · Frontiers in Immunology · 147
PDF
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper
2020 · Ibai Los-Arcos, Gloria Iacoboni, et al. · Infection · 144
PDF
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
2022 · Mi Kwon, Gloria Iacoboni, et al. · Haematologica · 136
PDF
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
2018 · Maria Castella, Anna Boronat, et al. · Molecular Therapy — Methods & Clinical Development · 126
PDF
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
2021 · Anne Mea Spanjaart, Per Ljungman, et al. · Leukemia · 115
PDF
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
2021 · Élie Azoulay, Pedro Castro, et al. · The Lancet Haematology · 107
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
2021 · Carlos A Garcia-Prieto, Lorea Villanueva, et al. · JNCI Journal of the National Cancer Institute · 64
PDF
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
2021 · Aina Oliver-Caldes, Raquel Jiménez, et al. · Journal for ImmunoTherapy of Cancer · 47
PDF
CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD
2024 · Jose Maria Cabrera-Maqueda, Maria Sepulveda, et al. · Neurology Neuroimmunology & Neuroinflammation · 42
PDF
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
2022 · Mariana Bastos-Oreiro, Antonio Gutierrez, et al. · Frontiers in Immunology · 40
CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
2022 · Clara Bueno, Susana Barrera, et al. · Blood · 39
Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
2022 · Nuria Martinez-Cibrian, Marta Español-Rego, et al. · Frontiers in Immunology · 36
PDF
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
2022 · Valentín Ortiz-Maldonado, Gerard Frigola, et al. · Frontiers in Oncology · 31
PDF
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
2023 · Ana Belen Moreno-Castaño, Sara Fernández, et al. · Journal for ImmunoTherapy of Cancer · 29
PDF
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
2021 · Valentín Ortiz-Maldonado, Susana Rives, et al. · Journal for ImmunoTherapy of Cancer · 27
PDF
Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma
2024 · Fabian Ullrich, Paul J Bröckelmann, et al. · Journal for ImmunoTherapy of Cancer · 24
PDF
The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel ( ARI ‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma
2023 · Núria Martínez‐Cibrián, Valentín Ortiz‐Maldonado, et al. · British Journal of Haematology · 24
PDF
Results of ARI ‐0001 CART19 cell therapy in patients with relapsed/refractory CD19 ‐positive acute lymphoblastic leukemia with isolated extramedullary disease
2022 · Valentín Ortiz‐Maldonado, Anna Alonso‐Saladrigues, et al. · American Journal of Hematology · 24
CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
2021 · Ariadna Bartoló-Ibars, Mireia Uribe-Herranz, et al. · Cancers · 21
PDF
A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia
2025 · Aïda Falgàs, Rodrigo Lázaro-Gorines, et al. · Blood · 20
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
2024 · Aina Oliver-Caldes, Marta Español-Rego, et al. · Clinical Cancer Research · 20
The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies
2024 · Helena Brillembourg, Núria Martínez‐Cibrián, et al. · British Journal of Haematology · 20
PDF
Works count: 224
Citation count: 2,142
H-index: 21
I10-index: 37
Year
Topic
Type